Coronavirus: Russia’s Sputnik V vaccine 91.6 per cent effective, British study says

Russia’s Sputnik V vaccine is 91.6 per cent effective against symptomatic Covid-19, according to results published in The Lancet on Tuesday that independent experts said allayed transparency concerns over the jab, which Moscow is already rolling out.

Sputnik V – named after the Soviet-era satellite – was approved in Russia months before results from its final-stage clinical trials were published, leading to scepticism from experts.

But the new analysis of data from 20,000 participants in Phase 3 trials suggests that the two-dose vaccination offers more than 90 per cent efficacy against symptomatic Covid-19.

“The development of the Sputnik V vaccine has been criticised for unseemly haste, corner cutting, and an absence of transparency,” said an independent Lancet commentary by Ian Jones of the University of Reading and Polly Roy of the London School of Hygiene and Tropical Medicine.

“But the outcome reported here is clear and the scientific principle of vaccination is demonstrated, which means another vaccine can now join the fight to reduce the incidence of Covid-19.”

09:50

SCMP Explains: What's the difference between the major Covid-19 vaccines?

SCMP Explains: What's the difference between the major Covid-19 vaccines?

The results suggest Sputnik V is among the top performing vaccines, along with the Pfizer/BioNTech and Moderna jabs that also reported more than 90 per cent efficacy.